A Physiologic and Pharmacological Basis for Implementation of Incretin Hormones in the Treatment of Type 2 Diabetes Mellitus
-
Published:2010-12
Issue:12
Volume:85
Page:S5-S14
-
ISSN:0025-6196
-
Container-title:Mayo Clinic Proceedings
-
language:en
-
Short-container-title:Mayo Clinic Proceedings
Author:
Freeman Jeffrey S.
Reference62 articles.
1. Banting Lecture: from the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus;DeFronzo;Diabetes,2009
2. Trajectories of glycaemia, insulin sensitivity, and insulin secretion before the diagnosis of type 2 diabetes: an analysis from the Whitehall II study;Tabak;Lancet,2009
3. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33);United Kingdom Prospective Diabetes Study Group;Lancet,1998
4. UK Prospective Diabetes Study 16: overview of 6 years' therapy of type II diabetes: a progressive disease;UK Prospective Diabetes Study Group;Diabetes,1995
5. Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49);Turner;JAMA,1999
Cited by
19 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献